 
  
 
  
Study Protocol: TTCRNE -1501: A Multicenter, Open Label Phase [ADDRESS_801573] Allograft (TTAX01)  
 
[STUDY_ID_REMOVED]  
 
Version 1.1 (05Feb2018)  
A Multicenter, Open Label Phase [ADDRESS_801574] Allograft (TTAX01)  
 
Protocol Number: TTCRNE -1501  
IND Sponsor:   TissueTech, Inc.  
[ADDRESS_801575]  
Miami, FL [ZIP_CODE]  
 
Version Number:  v. 1.1 
05-FEB -2018 
 
 
Summary of Changes from Previous Version:  
Affected 
Section(s)  Summary of Revisions Made Rationale 
1.1 Updated study population to 36 patients with 
approximately 12 sites  Adjusted study population based on the 
projected number of clinical sites to 
participate, and to enroll 3 patients/site  
3.0, 8.1.[ADDRESS_801576] per section 7.2  
5.2 Removed previous exclu sion #1 ‘the subject has 
another ulcer within 3cm of the index ulcer 
 
Removed previous exclusion #10 ‘The subject 
has tested positive for HIV or has AIDS’  Since there is no worsening criter ion of the 
index ulcer, any ulcer within close proximity 
to the index ulcer would be surgically 
addressed at the Initial Procedure Visit.  
Allowing patients with HIV or AIDS since there are no contraindications with TTAX01  
 
TissueTech, Inc. TTCRNE -1501  v 1.1  ii Added sepsis definition to previous exclusion 
#20, which is now exclusion #[ADDRESS_801577] for off -loading methods  
8.4.1, 8.4.2, 
[IP_ADDRESS], 8.4.6  Updated adverse event  (AE)  definition, reporting 
AEs, updating related terminology, updated 
Medical Monitor email  Provided clarity on AE definition, reporting of 
AEs in the electronic data capture system, and updated medical monitor email for SAE  
9.4.7  Updated sub- group analysis by [CONTACT_605323]- group analyses per FDA 
recommendation  
  
TissueTech, Inc. TTCRNE -1501  v 1.1  ii Table of Contents  
STATEMENT OF COMPLIANCE  .............................................................................................................................. 1  
1 PROTOCOL SUMMARY  ................................................................................................................................ 2  
1.1 Synops is ................................................................................................................................................. 2  
1.2 Schema  ................................................................................................................................................... 4  
1.3 Schedule of Activities (SoA)  .................................................................................................................. 6  
2 INTRODUCTION ............................................................................................................................................ 7  
2.1 Study Rationale  ...................................................................................................................................... 7  
2.2 Background  ............................................................................................................................................ 8  
2.3 Risk/Benefit Assessment  ...................................................................................................................... 11 
2.3.1  Known Potential Risks  ..................................................................................................... 11 
2.3.2  Known Potential Benefits  ................................................................................................. 11 
2.3.3  Assessment of Potential Risks and Benefits  ..................................................................... 11 
3 OBJECTIVES AND ENDPOINTS  ................................................................................................................ 12 
4 STUDY DESIGN ............................................................................................................................................ 13 
4.1 Overall Design  ...................................................................................................................................... 13 
4.2 Scient ific Rationale for Study Design  .................................................................................................. 14 
4.3 Justification for Dose ............................................................................................................................ 14 
4.4 End of Study Definition  ....................................................................................................................... 14 
5 STUDY POPULATION ................................................................................................................................. 14 
5.1 Inclusion Criteria  .................................................................................................................................. 15 
5.2 Exclusion Criteria  ................................................................................................................................. 15 
5.3 Lifestyle Considerations  ....................................................................................................................... 16 
5.4 Screen Failures  ..................................................................................................................................... 16 
5.5 Strategies for Recruitment and Retention  ............................................................................................. 17 
6 STUDY INTERVENTION  ............................................................................................................................. 17 
6.1 Study Intervention(s) Administration  ................................................................................................... 17 
6.1.1  Study Intervention Description  ......................................................................................... 17 
6.1.2  Dosing and Administration  ............................................................................................... 17 
6.2 Preparation/Handling/Storage/Accountability  ...................................................................................... [ADDRESS_801578] Storage and Stability  ........................................................................................... 19 
6.2.4  Preparation  ........................................................................................................................ 19 
6.3 Measures to Minimize Bias  .................................................................................................................. 20 
6.4 Study Intervention Compliance  ............................................................................................................ 20 
6.5 Concomitant Therapy  ........................................................................................................................... 21 
6.5.1  Rescue Medicine  ............................................................................................................... 21 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ................................................................................................................... 21 
7.1 Discontinuation of Study Intervention  ................................................................................................. 21 
7.2 Participant Discontinuation/Withdrawal from the Study ...................................................................... [ADDRESS_801579] to Follow -Up ................................................................................................................................ 22 
8 STUDY ASSESSMENTS AND PROCEDURES  .......................................................................................... 22 
8.1 STUDY ACTIVITIES BY [CONTACT_16990]  ........................................................................................................ 22 
8.1.1  Screening Period (within -7 Days from Initial Procedure Visit)  ....................................... 22 
8.1.2  Initial Procedure Visit (Visit BL/baseline)  ....................................................................... 25 
  
TissueTech, Inc. TTCRNE -1501  v 1.1  iii 8.1.3  Treatment Period [Visit 01 through Visit 15 (7 +/- 2 days)]  ............................................. 27 
8.1.4  Treatment Period [Visit 16 (7 +/- 2 days)]  ........................................................................ 31 
8.1.5  Confirmatory Period [Visit 17 and Visit 18 (7 +/- 2 days)]  .............................................. 31 
8.1.6  End of Treatment Period Visit (Visit 19) (14 +/- 2 days)  ................................................. 32 
8.2 Efficacy Assessments  ........................................................................................................................... 32 
8.3 Safety and Other Assessments  .............................................................................................................. 32 
8.4 Adverse Events and Serious Adverse Events  ....................................................................................... 32 
8.4.1  Definition of Adverse Events (AE) ................................................................................... 32 
8.4.2  Definition of Serious Adverse Events (SAE)  ................................................................... [ADDRESS_801580]  ................................................................................................. 36 
8.4.9  Reporting of Pregnancy .................................................................................................... 36 
8.5 Unanticipated Problems  ....................................................................................................................... 36 
8.5.1 Definition of Unanticipated Problems (UP) ...................................................................... 36 
8.5.2  Unanticipated Problem Reporting  ..................................................................................... 36 
8.5.3  Reporting Unanticipated Problems to Participants  ........................................................... 36 
9 STATISTICAL CONSIDERATIONS  ............................................................................................................ 37 
9.1 Statistical Hypotheses  ........................................................................................................................... 37 
9.2 Sample Size Determination  .................................................................................................................. 37 
9.3 Populations for Analyses  ...................................................................................................................... 37 
9.4 Statistical Analyses ............................................................................................................................... 37 
9.4.1  General Approach  ............................................................................................................. 37 
9.4.2  Analysis of the Primary Efficacy Endpoint(s)  .................................................................. 38 
9.4.3  Analysis of the Secondary Endpoint(s)  ............................................................................. [ADDRESS_801581] Keepi[INVESTIGATOR_007]  ................................................................................. 44 
10.2 Additional Considerations  .................................................................................................................... 46 
10.3 Abbreviations  ....................................................................................................................................... 47 
  
TissueTech, Inc. TTCRNE -1501  v 1.1  iv 10.4 Protocol Amendment History  ............................................................................................................... 48 
11 REFERENCES ................................................................................................................................................ 49 
12 Sponsor Signatures  .......................................................................................................................................... 55 
13 Investigator Signature  ..................................................................................................................................... 56 
 
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  1 STATEMENT OF COMPLIAN CE 
 
The trial will be carried out in accordance with International Conference on Harmonisation Good 
Clinical Practice ( ICH GCP) and  the following:  
 
• [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (21 CFR 
Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)  
 
Investigators and clinical trial site staff who are responsible for the conduct, management, or 
oversight of this  trials  have completed Human Subjects Protection and ICH GCP Training. 
 The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the Institutional Review Board ( IRB) for review and approval.  Approval of both 
the protocol and the consent form must be obtained before any participant is screened or enrolled.  Any amendment to the protocol wil l require review and approval by [CONTACT_99115].  In addition, a ll changes to the consent form will be IRB -approved; 
a determination will be made regarding whether  a new consent needs to be obtained from 
participants  who provided consent, using a previously approved consent form. 
  
 
(Remainder of page intentionally blank) 
  
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  2 1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  A Multicenter, Open Label Phase [ADDRESS_801582] Allograft (TTAX01) 
 
Study Des cription : It is hypothesized that application at [ADDRESS_801583] safety 
and efficacy when applied according to the protocol instructions, and measured according to the stated endpoints.  
 
Objectives:  
 Primary Objective:  To examine the safety and estimate the efficacy of 
TTAX01 plus standard care (SC) in achieving complete wound closure of complex non- healing diabetic foot ulcers with high risk factors of [1] 
ulcer depth indicating exposed 
bone, tendon, muscle, and/or joint 
capsule and [2] clinical suspi[INVESTIGATOR_605311]. 
 
 Summary of Secondary Objectives: To examine alternative measures 
of wound healing, progress towards healing, and healing among stated subsets, as well as to estimate  the influence of treatment on rates of 
amputation. 
 
Endpoint s: Primary Endpoint:  Proportion of subjects with c omplete wound healing  
by [CONTACT_605324] 16  
 
Secondary Endpoints: Various associated measures such as time to 
heal, proportion healed by [CONTACT_5875], and wound area reduction.  
 
Study Population:  Approximately 36 adults aged 18 years and older, with diabetes mellitus 
types 1 or 2, and non- ischemic, non- dorsal diabetic foot ulcer 
measuring 1 -10 cm2 inclusive with evidence of exposed bone, tendon, 
muscle and/or joint capsule and presumptive evidence of osteomyelitis . 
 
Phase:  2 
 
Description of 
Sites /Facilities  
Enrolling 
Participants:  Approximately twelve  sites specializing in care of diabetic foot ulcers, 
including inpatient hospi[INVESTIGATOR_605312], wound care centers, dermatology and 
vascular surgery clinics.  
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  3  
Description of Study 
Intervention : All subjects will receive aggressive debridement at baseline, followed 
by [CONTACT_605325]01, a  cryopreserved human 
umbilical cord  product derived from  human placental t issue. Test article 
is applied and surgically fixed in direct contact [CONTACT_605326], 
at 4 week intervals unless healing is evident, or when replacement of 
dislodged material is necessary .  
 
Study Duration:  Estimated time from first subject eligible and enrolled  to completion of 
statistical analysis is 18 months . 
 
Participant Duration:  The maximum time in study for any subject will be [ADDRESS_801584] Procedure 
Enrollment      Treatment  
Visits  
    Verification  
Visits  
   Exit Visit 19  
           Obtain informed consent. Screen potential participants by [CONTACT_605327]; 
obtain history, document. Perform baseline assessments and lab tests (Table 2 ). Obtain 
imaging to aid in diagnosis of osteomyelitis.  
Perform aggressive debridement in the operating room to remove infected and devitalized 
tissue. Obtain biopsies for histopathology  testing  and microbiology culture. Begin 
systemic antibiotics. Administer initial TTAX01 plus standard care . 
Follow -up assessments of study endpoints and safety  
Final Assessments  Enrollment 
target N=3 6 
Observe wound  for evidence of healing at weekly intervals, with wound cleaning, 
debridement, and management of any infection. Repeat study intervention at 4 -week 
intervals if the wound is not infected and is not showing signs of healing. 
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  5 Figure 2. Process diagram  
 
 
 
 
(Remainder of page intentionally blank) 
 
 
 
  Screening Visit SCR
•Total estimated screened n=47 (30% screen failure rate)
•Obtain informed consent, screen potential participants by [CONTACT_21198]
•Obtain history, document
•Obtain baseline laboratory and imaging studies for osteomyelitis
•Initiate empi[INVESTIGATOR_605313]/Initial Procedure
•Perform aggressive debridement in the operating room, obtain biopsies for histopathology and culture
•Verify that subject meets all criteria for enrollment
•Apply firs t TTAX01 Baseline debridement, Qualification
Visits 1-16 (7± 2 d)
•Observe wound weekly for healing or stalled, infected
•Re-treat at 4 week intervals if not infected, not healing
•Perform weekly cleaning and debridement; observe and interview for adverse events
•If the wound has closed, proceed to Visit 17. If the wound remains open at Visit 16, proceed to Visit 19
Follow- up assessments of study endpoints and safety Visits 17, 18 (7± 2 d)
•For subjects whose wound has closed, determine again if the wound remains healed or has re- opened
End of Study Exit Visit Visit 19 (14± 2 d)
•Verify wound healing, resolution of AEs,  assess vascular perfusion, obtain final lab tests ( Table 2 )Evaluations and re -treatments  
 
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  6  
1.3 SCHEDULE OF ACTIVITIES  (SOA)  
 
 
 
 
 
  

Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  7 2  INTRODUCTION  
 
2.1 STUDY R ATIONALE   
 
According to the [LOCATION_002] ( US) Centers for Disease Control, there were 29.1 million 
Americans of all ages or 9.3% of the population in 2014 who  had diabetes  (1) either diagnosed or 
undiagnosed, a figure that has increased by [CONTACT_605328] 1980 (2). An estimated 21 million 
persons were diagnosed with the disease, while an additional 8.1 million remain undiagnosed (1). 
By 2050, as many as [ADDRESS_801585] diabetes if the trend continues (2).  
One of the most prevalent complications of diabetes is the diabetic foot ulcer. Diabetic persons 
have approximately 25% risk of developi[INVESTIGATOR_007] a foot ulcer in their lifetime  (3) with an estimated 
annual incidence rate  of 0.5-3.0% (4-8). When the ulcer is non -healing, the dermal first line of 
defense is compromised for a prolonged period and the patient is susceptible to tissue loss that 
leads to limb amputation. Indeed, foot ulceration is the most common single precursor of lower extremity amputations among persons with diabetes and is a precursor to approximately 85% of 
the lower extremity amputations with in this population (3, 9-20). In the US, diabetes has been the 
most common underlying cause of non- traumatic lower extremity a mputations (21, 22) ; more than 
60% of non- traumatic lower extremity amputations occur in diabetic per sons (1). 
Over 73,000 non- traumatic lower -limb amputations are performed in the US for people with 
diabetes annually  (1). Unfortunately, after one major lower extremity amputation, the 5- year 
survival rate is estimated to be 50%  (14, 15) , worse than those of most malignancies  and second  
only to that of lung cancer  (14, 16) . Moreover, once amputation occurs, 50% of the patients will 
develop an ulcer in the contralateral limb within 5 year s (15). For amputation survivors, day -to-
day functioning is greatly impaired.  Many cannot walk, with or without the use of a cane or 
walker. A study found that in 2010, 22.8% of patients undergoing amputation of a lower extremity in the US  were readmitted to the hospi[INVESTIGATOR_79638] [ADDRESS_801586] rate of  re-admission among 
the procedures considered in the  study (23). Moreover, even  with the best of medical care, 
amputation and its aftermath are traumatic experiences that can be expected to produce depression as the patient copes with the social and financial consequences of disfigurement and loss of function. Collectively, one can envision a grave pi[INVESTIGATOR_605314]-healing foot ulcers that carry these high risks that may lead to amputation in this country and 
worldwide. 
Three major risk factors, i.e., [1] ulcer depth, [2] infection, and [3]  ischemia, have been recognized 
to complicate non- healing foot ulcers leading to limb amputation  (17). The first risk factor is “ulcer 
depth”. This clinical trial w ill enroll patients with the ulcer depth exhibiting exposed bone, tendon, 
muscle and/or joint capsule. It has been well known that these deep ulcers with extensive tissue 
loss are at high risk for infection-related ulcer complications including osteomyelitis  (24). 
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  8 The second risk factor is “infection”. While infection is not often implicated in the pathway leading 
to ulceration, it is a major risk factor in the causal pathway to  amputation (25, 26) . Contiguous 
spread of any infection of adjacent soft tissue into the bone of the foot will  complicate the ulcer, 
predisposing the patient to risk of osteomyelitis  (18),(19). Foot ulcers accompanied by [CONTACT_605329]-
threatening infections such as osteomyelitis have reported amputation rate as high as 51%  (27-29). 
Indeed, the presence of an infection is a major predisposing factor for diabetic foot amputations, as 85% of these amputations are preceded by [CONTACT_25747] (21, 30, 31) . The risk of amputation 
increases by [CONTACT_605330] (32).  
The third risk factor is “ischemia”. Critical limb ischemia (CLI) has been used to denote a subgroup of patients with a threatened lower extremity primarily due to chronic ischemia. Foot ulcers 
complicated by [CONTACT_605331] 17 -23% and a 
mortality rate of 33%  (33, 34) . Because CLI will compromise wound healing and because the 
standard of care calls for vascular consultation as well as potential revascularization procedures to 
address limb ischemia  (17), clinical trials conducted under the Sponsor’s IND exemption will only 
enroll those pa tients with diabetic foot ulcer  in which the vascular perfusion status is adequate to 
support healing.  
Collectively, the Inclusion and Exclusion criteria stated in this  protocol allow us to enroll patients 
with a chronic diabetic foot ulcer that carries the severity of Wagner Grade 3 or worse (on a scale 
of 0 to 5 based on Wagner Classification System). This open label pi[INVESTIGATOR_605315] a proposed Phase 3 pi[INVESTIGATOR_16076], including ease of compliance 
with various decision points in the protocol (e.g., antibiotic use, debridement in the operating room, 
whether to treat with TTAX01 or wit hhold treatment), and to provide a refined estimate of 
treatment response.   
 
2.[ADDRESS_801587] a depth exhibiting exposed bone, tendon, muscle, and/or joint capsule. Apligraf
® and Dermagraft® are not indicated for ulcers with exposed bone, tendon, muscle, and/or 
joint capsule and are contraindicated for use on clinically infected ulcers or manifesting ischemia 
(e.g., A nkle Brachial Index (A BI) less than 0.60) or infection (e.g., osteomyelitis) . Exposure of 
bone, tendon, muscle, and/or joint capsule, ischemic wounds (e.g., ABI less than 0.60), clinically 
infected ulcers and osteomyelitis are the exclusion criteria in clinical trials of various advanced skin substitutes approved for chronic foot ulcers of various etiologies. Only Theraskin
® carries 
indication for use in exposed tendon, joint and/or bone. It should be noted that the approval of Theraskin
® is supported by a retrospective observational study or clinical case studies  (35-37) 
rather than a prospective randomized and controlled clinical trial. In one study of 188 patients  
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  11 muscle and/or joint capsule and [2]  clinical su spi[INVESTIGATOR_605311], so as to reduce the 
likelihood of ulcer- related complications including limb amputation.  
 
2.3 RISK/BENEFIT ASSESSM ENT   
 
2.3.1  KNOWN POTENTIAL RISKS  
 
The major risk associated with use of human tissue as a temporary, non- engrafting therapeutic is 
the transmission of infectious agents. (63) This risk is minimized though careful donor screening 
and Good T issue Practices. Decellularization removes any risk of potential graft vs. host reactions. 
A review of the literature indicates that various cell and tissue based products tested as therapeutics 
for non- healing wounds show no differences in adverse event profile compared with standard care 
(SC). Two ongoing controlled trials of NEOX® CORD 1K® for treatment of DFU show no pattern 
of treatment emergent adverse events ass ociated with use of the product  ([STUDY_ID_REMOVED], 
[STUDY_ID_REMOVED]). The procedures required by [CONTACT_605332].  
 
2.3.2  KNOWN POTENTIAL BENE FITS  
 
Three published retrospective case series provide an estimate of the complete healing rate when treating chronic DFU with NEOX
® CORD 1K®, a marketed HCT/P [ADDRESS_801588] under Good Manufacturing Practices. 
 
Ref Patients  Baseline wound 
area  Number of 
applications  Complete 
healing  Mean time 
to heal  
(64) 
Retro case 
series  31 patients, 33 wounds; 
complex DFU with 
osteo myelitis  15.6 ± 17.7 cm2  1.24 ± 0.44  26/33 (78.8%)  16.0 ± 9.3 
weeks  
(65) 
Retro case 
series  29 patients, 32 wounds; 
DFU  10.6 ± 2.15cm2  1.68 ± 0.18  28/32 (87.5%)  13.8 ± 1.95 
weeks  
(66) 
Retro case 
series  57 patients, 64 wounds of 
the lower extremity  6.85 ± 16.29 cm2  3.43 ± 2.42  51/64 (79.7%)  5.53 ± 3.93 
weeks  
 
The anticipated immediate benefit is healing of the open diabetic foot ulcer. The associated long term benefit is expected to  be a reduced risk of amputation. In the published experience of Caputo 
(64), only one of 15 planned amputations was necessary following intervention with NEOX
® 
CORD 1K®. 
 
2.3.[ADDRESS_801589] meet all of the following criteria:  
1. The subject has signed the informed consent form  
2. The subject is male or female, at least [ADDRESS_801590]’s index ulcer is located on the plantar surface, inter digital, heel, or late ral or 
medial surface of the foot  
5. The subject has an index ulcer with visible margins having an area ≥1.0 cm
2 to ≤ 10.[ADDRESS_801591]’s index ulcer extends beyond the dermis, into subcutaneous  tissue with 
evidence of exposed bone, tendon, muscle and/or joint capsule 
7. The subject presents with history, signs or symptoms leading to a clinical suspi[INVESTIGATOR_605316] P robe to Bone (PTB) 
and any of the following: radiographic (x -ray, M agnetic Resonance Imaging (MRI) , or 
bone scan) or evidence of bone necrosis 
8. The subject has an ABI ≥ 0.7 to ≤ 1.3 or TcPO2 ≥ 40 mmHg on the dorsum of the affected foot, or Great Toe Pressure ≥ [ADDRESS_801592] is willing to follow the instructions of the trial Investigator  
 
5.2 EXCLUSI ON CRITERIA  
 
An individual who meets any of the following criteria will be excluded from participation in this 
study:  
1. The subject’s index ulcer is primarily located on the dorsal surface of the foot 
2. The subject’s index ulcer can be addressed by [CONTACT_605333]  
3. The subject has a glycated hemoglobin A1c (HbA1c) level of > 12% 
4. The subject has a serum albumin level ≤ 2.0 g/dL  
5. The subject has a white blood cell count < 2.0 x109/L, neutrophils < 1.0 x109/L, or platelets 
< 100 x109/L 
6. The subject has been on oral steroid use of > 7.5 mg daily for greater than seven (7) 
consecutive days in [ADDRESS_801593] is currently taking the type 2 diabetes medicine canagliflozin (Invokana ™, 
Invokamet™, Invokamet XR™) 
9. The subject has malignancy or a history of cancer, other than non -melanoma skin cancer, 
in five years before Screening  
10. The subject is pregnant  
11. The subject is a nursing mother 
12. The subject is a woman of child -bearing potential who is unwilling to avoid pregnancy or 
use an appropriate form of birth control (adequate birth control methods are defined as: 
topi[INVESTIGATOR_2855], oral, implantable, or injectable contraceptives; spermicide in conjunction with a barrier such as a condom or diaphragm; IUD; or surgical sterilization of partner). 
13. The subject is unable to sustain offloading as defined by [CONTACT_760] 
14. The subject has an allergy to primary or secondary dressing materials used in this trial  
15. The subject has an allergy to Amphotericin B, Dulbecco’s Modified Eagle Medium 
(DMEM) or glycerol  
16. The subject’s index ulcer is over an acute Charcot deformity 
17. The subject has had previous use of NEOX
®, CLARIX®, or TTAX01 applied to the index 
ulcer  
18. Per Investigator’s discretion the subject is not appropriate for inclusion in the trial, e.g., undergoing surgical treatments listed in the protocol or the subject cur rently has sepsis , i.e., 
life-threatening organ dysfunction caused by a dysregulated host response to infection 
 
5.[ADDRESS_801594] with appropriate specialty training and experience. The need for offloading of the wound requires compliance with daily wearing of the offloading device, which may limit ambulation to some degree.  
5.4 SCREEN FAILURE S 
 Screen failures are defined as p otential subjects  who consent to participate in the  trial but are not 
subsequently entered . Screen failure information will be captured to ensure transparent reporting 
of screen failure participants , to meet the Consolidated Standards of Reporting Trials (CONSORT) 
publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any serious adverse event (SAE).  
 Individuals  who do not meet the criteria for participation in this trial because of an abnormal lab 
test result, wound size out of range, current treatment with an excluded medication or inadequate 
Open Label Phase [ADDRESS_801595] article are as follows:  
  
1. If frozen, allow TTAX01 to sit at controlled room temperature in its original unopened 
packaging for at least [ADDRESS_801596] photographic image in order to make a determination of wound closure. If this opi[INVESTIGATOR_605317]’s opi[INVESTIGATOR_1649], the wound will be recorded as healed. If the independent reviewer finds reason to disagree with the Investigator, a third independent reviewer will examine all of the photographs for the purpose of breaking the tie.   
6.[ADDRESS_801597] compliance will be 
based on observation of the offloading device at each visit for evidence of wear, by [CONTACT_605334] / therapi[INVESTIGATOR_014], and queries regarding dosing of any 
antibiotics. No blood testing or other test procedure will be utilized for determination of compliance. Diaries will not be used. 
  
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  21  
6.5 CONCOMITANT THERAPY  
 
Systemic anti-microbials may be used as prescribed. Wound cleansing with a neutral, non-
irritating and non- toxic solution is recommended at the discretion of the Investigator. Sterile saline, 
non-ionic cleanser, or hypochlorous acid are recommended. 
Canagliflozin, a type 2 diabetic medication, also referred to as Invokana, Invokamet, and 
Invokamet XR, is not permitted throughout the duration of the screening, treatment and 
confirmation of closure periods. 
Concomitant therapi[INVESTIGATOR_605318]. They include topi[INVESTIGATOR_90413], antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide, enzymes, negative pressure wound therapy, hyperbaric oxygen, growth factors, living skin, dermal substitutes, silver -containing products, amniotic membrane or 
umbilical cord products or other advanced biological therapi[INVESTIGATOR_014], or revascularization procedures (e.g.,  endoscopic perforator surgery, superficial venous ablation, endovenous laser ablation, 
valvuloplasty, free flap transfer with microvascular anastomoses), and Achilles tendon lengthening. 
6.5.1  RESCUE MEDICINE  
 Not applicable.  
 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT  
DISCONTINUATION/ WITHDRAWAL  
  
7.[ADDRESS_801598] 
NEOX
® CORD 1K®, which has an outstanding safety record, there is no a priori  expectation of 
needing to suspend or terminate the trial for unexpected adverse events.   
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE S TUDY  
 All subjects have the right to discontinue the trial at any time. The Investigator may also withdraw a subject from the trial at any time if they deem it medically necessary. The reason for discontinuation should be documented and trial staff should attempt to bring the subject in for an Early Termination Visit and perform all applicable assessments as appropriate listed under the E nd 
of Treatment Period Visit (Visit 19) for discontinuations that occur during the Treatment Period. 
Subjects may be discontinued from the trial for the following reasons: • Adverse Event (including illness) 
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  22 • Subject withdrawal of consent 
• The Sponsor or Investigator terminates the trial • Lost to follow-up • Product- related > Grade 2 skin or systemic allergic reaction  
• Ulcer -related complications (i.e., life -threatening, infection -related sepsis complications)  
• Subsequent limb amputation (i.e., full amputation involving the index ulcer anatomic location) 
 In the event of a subject’s withdrawal, the Investigator will promptly notify the medical monitor and will make every effort to complete all procedures at either the End of Treatment Period Visit. Even if removed subjects have been removed from the trial or if an adverse event remains ongoing, Investigators should follow up with subjects as per their standard medical practice.  
Discontinued subjects will not be replaced.  Simultaneous screening at multiple sites may result in 
an allowable modest over- enrollment.  
7.[ADDRESS_801599]’s di abetes 
should be contact[CONTACT_605335]’s current health status.  
8 STUDY ASSESSMENTS AN D PROCEDURES  
 
8.1 STUDY ACTIVITIES BY [CONTACT_16990]  
 
8.1.1  SCREENING PERIOD ( WITHIN -7 DAYS FROM INITIAL  PROCEDURE 
VISIT)  
 
[Purpose]: To determine the trial eligibility by [CONTACT_243828]/exclusion criteria based on the medical information available, clinical assessment, clinical laboratory testing, imaging studies and interview with subject. 
Each subject who enters Screening will be assigned a subject ID number for traceability.  The 
subject ID will consist of a [ADDRESS_801600] number (i.e. 01- 001, etc.).  
Any subject who signs an informed consent, but fails to meet the required eligibility criteria is considered to be a Screen Failure. Screen Failure subjects should have their demographic 
information captured with the reason for screen failure specified. If  a subject fails to meet all 
criteria after two screening attempts, the subject may not be enrolled into the trial. A new informed 
consent is required for each screening attempt. All procedures, excluding qualifying lab and 
Open Label Phase [ADDRESS_801601]. An 
AE can be any unfavorable and unintended sign (for example, an abnormal laboratory finding), 
symptom, or disease. The Investigator, or his/her designee, will document AEs.  AE data will be 
entered onto the appropriate source and electronic case report form (eCRF). Adverse events will be coded using Medical Dictionary for Regulatory Activities (MedDRA). 
All AEs should be followed during the trial period. The Investigator should use his/her discretion 
in ordering additional tests as necessary to monitor the resolution of such events. Event outcome 
at resolution or at time of last follow up will be recorded as event resolved, resolve d with sequelae, 
ongoing at discontinuation, or death. Investigators should continue to follow up events of concern outside of the trial per their standard of care. The trial database may be finalized in these cases 
with events noted as ongoing. 
The Invest igator should consider adverse events both as they relate to the investigational product 
and as they relate to the procedures involved in the trial such as debriding tissue. The Investigator 
is responsible for determining initial relationship , expectedness , and severity of adverse events.  
All adverse events must be reported regardless of whether or not they are considered to be related 
to the test article.  
 
8.4.2  DEFINITION OF SERIOU S ADVERSE EVENTS (SAE)  
 A serious adverse event (SAE) is defined by [CONTACT_54767]: death, life -threatening AE, requires hospi[INVESTIGATOR_226526], a persistent or significant disability/incapacity, or a congenital anoma ly/birth defect.  
Important medical events that may not result in death, be life threatening, or require hospi[INVESTIGATOR_12475], based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgi cal intervention to prevent one of the outcomes listed 
in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in su bject hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  
 
8.4.3  CLASSIFICATION OF AN ADVERSE E VENT  
 
[IP_ADDRESS]  SEVERITY OF EVENT  
 The severity of all AE, will be assessed by [CONTACT_605336], moderate, or severe.  Severity will be graded according to the following definitions: 
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  34 • Mild:  The subject experiences awareness of symptoms but these are easily tolerated or 
managed without specific treatment.  
• Moderate:  The subject experiences discomfort enough to cause interference with usual 
activity, and/or the condition requires specific treatment. 
• Severe:  The subject is incapacitated with inability to work or do usual activity, and/or the 
event requires significant treatment measures.  
 
[IP_ADDRESS]  RELATIONSHIP TO STUDY INTERVENTION  
The relationship of the event to the investigational product should be determined by [CONTACT_9532] [INVESTIGATOR_605319]:  
Not Related:  The event is most likely produced by [CONTACT_1605]’s clinical 
condition, intercurrent illness, or concomitant drugs, and does not follow a known response 
pattern to the trial product which makes a causal relationship unlikely. 
Related:  The event follows a temporal relationship or known response pattern to the trial 
product, and cannot be reasonably explained by [CONTACT_1605]'s clinical 
condition, intercurrent illness, or concomitant drugs.   
 
[IP_ADDRESS]  EXPECTEDNESS  
 
As with t he use of any human tissue, the possibility of infectious agent transmission cannot be 
completely eliminated although all screening and microbial testing results were satisfactory for the tissue and tissue donor. Possible significant adverse events include  microbial infection and 
transmission of viral disease.  
 Expected adverse events non -related to the product are those post -surgical conditions consistent 
with any dermal debridement and excoriation of an ulcer. Potential adverse events for all research subjects in this trial intrinsic to the nature of DFUs: bleeding, hematoma, cellulitis, pain, deteriorating ulcer exudation, erythema, edema, infections including deep tissue infections (osteomyelitis), and occurrence of new ulcers. 
8.4.4  TIME PERIOD AND FREQ UENCY FOR EVENT ASSESSMENT  AND 
FOLLOW -UP 
The occurrence of an adverse event ( AE) or serious adverse event ( SAE ) may come to the attention 
of study personnel during study visits and interviews of a study participant presenting for medical care, or upon review by a study monitor.  All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate  case report form  (CRF ). Information to be collected includes event description, 
date of onset, clinician’s assessment of severity, relationship to study product (assessed only by 
[CONTACT_8703] a diagnosis)  confirmed by [CONTACT_079] , 
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  35 and date of resolution/stabilization of the event. All AEs occurring while on study must be 
documented appropriately regardless of relationship.  
 Any medical condition that is present at the time that the participant is screened will be considered as baseline medical history and not reported as an AE. However, if the study participant’s condition 
deteriorates at any time during the study, it will be recorded as an AE.  
 Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865].  The Investigator  will record all reportable events with start dates occurring any time after informed 
consent is obtained until the final study visit.  At each study visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit.  Event outcome at resolution or at time of last follow up will be recorded as “event resolved”, “resolved with sequelae”, “ongoing at 
discontinuation”, or “death”.  
8.4.5  ADVERSE EVENT REPORT ING  
 Disease Related Events expected in this population (angina, neuropathy, nephropathy, urinary tract infection, erectile dysfunction, retinopathy, hypoglycemic events) may be reported by [CONTACT_605337], or if they appear to have a causal relationship to the test article. A ll adverse events must be reported in the subject’s source 
documents , and recorded on an Adverse Event Case Report Form regardless of whether or not they 
are considered to be related to the test article.    
 
8.4.[ADDRESS_801602] be completed for all serious adverse events and submitted 
within 24 hours of the Investigator's knowledge of the event and to the Institutional Review Board/Independent Ethics Committee, according to their reporting requirements. When new 
significant information is obtained as well as when the outcome of an event is known, the 
Investigato r must provide this information as soon as it becomes available. Depending on the 
nature of the adverse event, copi[INVESTIGATOR_9238]’s medical records as well as results of any relevant laboratory tests performed maybe required to be submitted. If the subj ect was hospi[INVESTIGATOR_057], a copy 
of the discharge summary should be forwarded as soon as it becomes available. In certain cases, a letter from the Investigator that summarizes the events related to the case may be required.  
Serious adverse events must be reported using the eCRF system (preferred), or via telephone or email, to the following representative within 24 hours of the Investigator's knowledge of the event:  
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  37  
Not applicable.  
9 STATISTICAL CONSIDERATIONS   
 
9.1 STATISTICAL HYPOTHES ES 
 This pi[INVESTIGATOR_605320] , to be described in greater detail in a separate Statistical Analysis Plan . 
 
9.2 SAMPLE SIZE  DETERMINATION  
 It is expected that 4 7 potential subjects will be screened in order to find 36 who qualify for this 
trial (screen failure rate 30%). The target number 36  is selected based on the law of large numbers, 
which holds that sample sizes less than 25 are more likely to produce skewed distributions of observed values, while sample sizes greater than 25 should generate a bell shaped distribution of observed values whose mean approaches the expected value as sample size increases.  
The dropout rate is expected to be ~10%. As numbers between [ADDRESS_801603] dropouts.  
9.3  POPULATIONS FOR ANALYSES  
 The Intent -to-Treat (ITT) population will consist of all enrolled  subjects. The ITT population is 
the primary efficacy population and will be used to conduct all analyses on primary and secondary efficacy endpoints. 
The Per Protocol (PP) population is a subset of subjects in the ITT and is the secondary efficacy 
population.  The PP population will be defined as all qualified and treated  subjects meeting 
inclusion and exclusion criteria and completing the study treatment as planned in the protocol, with no major protocol deviations during the 16- week Treatment Period. Major protocol deviations 
will be determined by [CONTACT_605338]. Subjects found to have major protocol deviations will be excluded from the PP population. 
The Safety Population includes all subjects who underwent treatment, regardless of protocol 
compliance. The Safety Population will be used for the analysis of safety endpoints.  
9.4 STATISTICAL ANALYSES  
 
9.4.1  GENERAL APPROACH  
 Categorical data will be presented as percenta ges. Continuous data will be presented as means ± 
standard deviation, median and range. 
 
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  41 (f) Those aspects of the trial that are experimental.  
 
(g) The reasonably foreseeable risks or inconveniences to the subject and, when applicable, to an embryo, fetus, or nursing infant. 
 (h) The reasonably expected benefits. When there is no intended clinical benefit to the subject, the subject should be made aware of this.  (i) The alternative procedure(s) or course(s) of treatment that may be available to the subject,  and 
their important potential benefits and risks.  
 (j) The compensation and/or treatment available to the subject in the event of trial- related injury.  
 (k) The anticipated prorated payment, if any, to the subject for participating in the trial.  
 (l) The anticipated expenses, if any, to the subject for participating in the trial.  
 (m) That the subject’s participation in the trial is voluntary and that the subject may refuse to participate or withdraw from the trial, at any time, without penalty or loss of benefits to which the subject is otherwise entitled.  
 (n) That the monitor(s), the auditor(s), the IRB/IEC, and the regulatory authority(ies) will be granted direct access to the subject’s original medical records for verification of clinical trial procedures and/or data, without violating the confidentiality of the subject, to the extent permitted by [CONTACT_29694], by [CONTACT_2960] a written informed consent form, the subject or the subject’s legally acceptable representative is authorizing such access.  
 (o) That records identifying the subject will be kept confidential and, to the extent permitted by [CONTACT_29695]/or regulations, will not be made publicly available. If the results of the trial are published, the subject’s identity will remain confidential.  
 (p) That the subject or the subject’s legally acceptable representative will be informed in a timely manner if information becomes available that may be relevant to the subject’s willingness to continue participation in the trial.  
 (q) The person(s) to contact [CONTACT_439966], and whom to contact [CONTACT_99822]- related injury.  
 (r) The foreseeable circumstances and/or reasons under which the subject’s participation in the trial may be terminated.  
 (s) The expected duration of the subject’s participation in the trial.  
 (t) The approximate number of subjects involved in the trial.  
[IP_ADDRESS]   CONSENT PROCEDURES AND DOCUMENTATION  
Open Label Phase [ADDRESS_801604] ( IRB)-approved and the participant will be asked 
to read and review the document. The investigator will explain the research study to the participant and answer any questions that may arise. A verbal explanation will be provided in terms suited to the participant’s comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants.  Participants will have the opportunity to carefully review the written consent form and ask questions prior to signing.  The participants will have the 
opportunity to discuss the study with their family or surrogates or think about it prior to agreeing to participate. Participants will be informed that participation is voluntary and that they may 
withdraw from the s tudy at any time, without prejudice.  A copy of the informed consent document 
will be given to the participants for their records. The informed consent process will be conducted and documented in the source document (including the date), and the form signed, before the participant undergoes any study -specific procedures. The rights and welfare of the participants will 
be protected by [CONTACT_183791] e to participate in th is study.  
  
Only authorized trial staff should obtain consent and the most currently approved IRB consent form must be used. 
10.1.2   STUDY DISCONTINUATIO N AND CLOSURE  
 The trial may be terminated at any time by [CONTACT_605339], if the Investigator does not adhere to the protocol, or if, in the Sponsor’s judgment, there are no further benefits to be achieved from the trial. In the event that the clinical development of the investigational product is discontinued, the Sponsor shall inform  all trial Investigators/institutions 
and regulatory authorities. 
To ensure subject safety, the following approach is included to allow suspension or termination of 
the trial should a serious unforeseen risk arise : in the event that there are 2 reports of the same 
serious, unexpected and related adverse event, the Medical Monitor will within 5 calendar days of 
notification of the second event make a recommendation to Sponsor senior management  whether to enhance surveillance, suspend enrollment, halt all further exposures, terminate the trial or continue without change. 
If suspended, the trial may resume once concerns about safety, protocol compliance, and data 
quality are addressed, and satisfy the sponsor, IRB and/or FDA.  
10.1.[ADDRESS_801605] party without prior written approval of the sponsor.   
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  45 Data collection is the responsibility of the clinical trial staff at the site under the supervision of the 
site investigator. Refer to the eCRF completion guidelines fo r eCRF completion, correction, and 
transmission procedures. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.   
 All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.  Hardcop ies of  study visit worksheets  may be provided for use as source 
document worksheets for recording data for each participant enrolled in the study.  Data recorded in the electronic case report form ( eCRF ) derived  from source documents should be consistent 
with the data recorded on the source documents.   Clinical data (including adverse e vents ( AEs), concomitant medications, and expected adverse 
reactions data) and clinical laboratory data will be entered via eDC into iMedNet , a [ADDRESS_801606] protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents.  
[IP_ADDRESS]   STUDY RECORDS RETENT ION  
 All records and documents pertaining to the trial including, but not limited to, data and source documents, will be maintained by [CONTACT_13177] a period of [ADDRESS_801607] the Sponsor prior to the destruction of any trial records.  The Investigator will promptly notify the Sponsor in the event of accidental loss or destruction of any trial records. 
 
[IP_ADDRESS]   PROTOCOL DEVIATIONS  
 A protocol deviation is any noncompliance with the clinical trial protocol  or ICH GCP  
requirements. The noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result of serious or repeat ed deviations, corrective and preventative actions 
are to be developed by [CONTACT_3483].   It is the responsibility of the site investigator to use continuous vigilance to identify and report 
deviations . The Investigator may not deviate from the protocol without a formal protocol 
amendment having been established and approved by [CONTACT_605340], except when necessary to eliminate imminent hazards to the patient or when the change(s) involve only logistical or administrative aspects of the trial. A deviation may result in the patient having to be withdrawn from the trial, render ing that patient non -evaluable.  
 
[IP_ADDRESS]   PUBLICATION AND DATA SHARING POLICY  
 
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  46 Agreements regarding publication and data sharing are found in the individual Clinical Trial 
Agreements between the Sponsor and each Investigator. At a minimum, the trial and its results will be posted on ClinicalTrials.Gov. 
 
[IP_ADDRESS]   CONFLICT OF  INTEREST P OLICY  
 Each investigator will be asked to complete a financial disclosure prior to the initiation of this study, and one year following database lock.  
10.[ADDRESS_801608]  
IB Investigator’s Brochure  
ICH International Conference on Harmonisation   
ICMJE  International Committee of Medical Journal Editors  
IND Investigational New Drug Application  
IRB Institutional  Review Board  
ISO International Organization for Standardization  
ITT Intention -To-Treat  
MedDRA  Medical Dictionary for Regulatory Activities  
MSDS  Material Safety Data Sheet  
NCT  National Clinical Trial  
PI [INVESTIGATOR_605321] & Soft Tissue Infections  
UP Unanticipated Problem  
US [LOCATION_002]  
 
  
Open Label Phase 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  48 10.4 PROTOCOL  AMENDMENT  HISTORY  
 
Version  Date  Description of Change  Brief Rationale  
1.0 01JUN2017  Original issue   
1.1 24Jan2018  Amendment #1  Updates to the protocol were 
made to improve the 
implementation and 
execution of the pi[INVESTIGATOR_605322] 2 Pi[INVESTIGATOR_605310]01 in Complex DFU  Version  1.1 
Protocol 1501  05-FEB -2018  
TissueTech, Inc. CONFIDENTIAL  56 13 INVESTIGATOR SIGNATU RE 
Study Title:  A Multicenter, Open Label Phase [ADDRESS_801609] Allograft (TTAX01) 
Study Number:  TTCRNE - 1501  
 
Amendment  Version 
Date:  
 [ADDRESS_801610] and terms of the trial specified herein.  In particular, I/we 
have agreed to:  
 
1. Abide by [CONTACT_605341] (Contract)  
2. Maintain confidentially and assure security of all confidential documents such as the 
protocol, product information documents, final trial reports, manuscript drafts, unpublished data, correspondence, etc.  
3. Assure access by [CONTACT_605342].  
4. Obtain Institutional Review Board approval of trial, any amendments to the trial, recruitment advertisements, informed consent document, and periodic re-approval as required. 
5. Keep the Institutional Review Board and Sponsor informed of serious adverse events and periodically report status of the trial to them as required.  
6. Obtain written informed consent from each participant or his/her legal representative. 
7. Make i mmediate reports of serious adverse events (SAE) to the Sponsor or designee. 
8. Cooperate fully with any trial- related Good Clinical Practice audit as performed by [CONTACT_429]’s representatives. 
9. Abide by [CONTACT_114212]/authorship guidelines establishe d at the outset of the trial.  
  
Investigator’s Signature:  ___________________________________________  
Investigator’s Name (please print):  ___________________________________________  
Date:  ___________________________________________  
 